EMA Pilots Reduced Parallel Trade Fee To Improve Availability Of Medicines In Malta
This article was originally published in SRA
The European Medicines Agency has launched a one-year pilot to help increase the availability of centrally authorized medicines in Malta by charging a reduced fee from companies involved in parallel distribution of medicines to the country1,2.
You may also be interested in...
The European Medicines Agency is charging a reduced fee for parallel distribution of centrally authorized medicines to smaller EU member states under a new initiative that aims to improve the availability of medicines. Malta and Latvia have joined in, and two other member states have showed interest in the initiative, which will end in July 2018.
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.